No CVD event | CVD event | |
---|---|---|
N | 1248 | 201 |
Male sex (%) | 622 (49.8) | 119 (59.2)* |
Age (years) | 65.4 [60.7, 70.2] | 68.6 [63.3, 72.1]** |
Employed (% yes)a | 529 (42.4) | 72 (35.8) |
Smoking (% yes) | 191 (15.3) | 36 (17.9) |
Clinical measures | ||
Body mass index (kg/m2) | 27.0 [24.1, 30.4] | 27.6 [25.3, 30.5]* |
Systolic blood pressure (mmHg) | 133 (17.3) | 136 (17.8)* |
Diastolic blood pressure (mmHg) | 82 (10.4) | 83 (10.5) |
Total cholesterol (mmol/l) | 5.5 (0.9) | 5.5 (1.0) |
High density lipoprotein cholesterol (mmol/l) | 1.5 [1.1, 1.9] | 1.5 [1.2, 1.6]* |
Low density lipoprotein cholesterol (mmol/l) | 3.3 (0.8) | 3.2 (1.1) |
Triacylglycerol (mmol/l) | 1.0 [0.7, 1.5] | 1.2 [0.9, 1.6] |
HbA1c (%) | 5.7 [5.5, 6.0] | 5.8 [5.5, 6.1]** |
HbA1c (mmol/mol) | 39 [37, 42] | 40 [37, 43]** |
Albumin creatinine ratio | 87 [49, 114] | 86 [35, 114] |
Estimated glomerular filtration rate (ml/min/1.73m2) | 79.4 [70.6, 88.0] | 77.0 [68.0, 87.0]* |
Medication use | ||
Any anti-diabetic drug (%) | 61 (4.9) | 12 (6.0) |
Any anti-hypertensive drug (%) | 474 (38.3) | 100 (50.0)** |
Any lipid-lowering drug (%) | 303 (24.5) | 55 (27.5) |
Aspirin (%) | 164 (13.2) | 45 (22.5)** |
Physical activity behavior | ||
Monitor wear time (days) | 6.6 (1.3) | 6.7 (1.2)* |
Physical activity energy expenditure (kJ/kg/day) | 31.0 [22.0, 42.0] | 28.0 [21.0, 39.0]* |
Light intensity physical activity (h/day) | 4.8 (1.8) | 4.5 (1.7) |
MVPA (min/day) | 29.8 [12.0, 56.3] | 24.0 [7.3, 44.7]** |
MVPA in bouts ≥ 10 min (min/day) | 8.2 [0.0, 24.4] | 4.4 [0.0, 18.7]* |
MVPA guidelines ≥ 30 min/day (%) | 532 (42.6) | 72 (35.8) |
Vigorous physical activity (min/day) | 0.0 [0.0, 0.3] | 0.0 [0.0, 0.1] |
Awake sedentary time (h/day) | 12.0 (2.2) | 12.4 (2.3)* |